BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 27565521)

  • 21. Prevalence of decisional regret among patients who underwent allogeneic hematopoietic stem cell transplantation and associations with quality of life and clinical outcomes.
    Cusatis RN; Tecca HR; D'Souza A; Shaw BE; Flynn KE
    Cancer; 2020 Jun; 126(11):2679-2686. PubMed ID: 32154926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pretransplantation Exercise and Hematopoietic Cell Transplantation Survival: A Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0902).
    Wingard JR; Wood WA; Martens M; Le-Rademacher J; Logan B; Knight JM; Jacobsen PB; Jim H; Majhail NS; Syrjala K; Rizzo JD; Lee SJ
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):161-164. PubMed ID: 27742574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell Transplantation.
    Patel SS; Rybicki LA; Corrigan D; Bolwell B; Dean R; Liu H; Gerds AT; Hanna R; Hill B; Jagadeesh D; Kalaycio M; Pohlman B; Sobecks R; Majhail NS; Hamilton BK
    Biol Blood Marrow Transplant; 2018 May; 24(5):1029-1034. PubMed ID: 29369800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fatigue in Hematopoietic Cell Transplantation Survivors: Correlates, Care Team Communication, and Patient-Identified Mitigation Strategies.
    Ullrich CK; Baker KK; Carpenter PA; Flowers ME; Gooley T; Stevens S; Krakow EF; Oshima MU; Salit RB; Vo P; Connelly-Smith L; Lee SJ; Wood WA
    Transplant Cell Ther; 2023 Mar; 29(3):200.e1-200.e8. PubMed ID: 36494015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
    Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research.
    Verneris MR; Lee SJ; Ahn KW; Wang HL; Battiwalla M; Inamoto Y; Fernandez-Vina MA; Gajewski J; Pidala J; Munker R; Aljurf M; Saber W; Spellman S; Koreth J
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1783-9. PubMed ID: 26055300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.
    Kołodziejczak M; Gil L; de la Camara R; Styczyński J;
    Ann Hematol; 2021 Mar; 100(3):763-777. PubMed ID: 33491135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Driving Distance and Patient-Reported Outcomes in Hematopoietic Cell Transplantation Survivors.
    Banerjee R; Yi JC; Majhail NS; Jim HSL; Uberti J; Whalen V; Loren AW; Syrjala KL
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):2132-2138. PubMed ID: 32781287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level.
    Fingrut W; Law A; Lam W; Michelis FV; Viswabandya A; Lipton JH; Kumar R; Mattsson J; Kim DDH
    Ann Hematol; 2021 Mar; 100(3):789-798. PubMed ID: 33415423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low Socioeconomic Status, Adverse Gene Expression Profiles, and Clinical Outcomes in Hematopoietic Stem Cell Transplant Recipients.
    Knight JM; Rizzo JD; Logan BR; Wang T; Arevalo JM; Ma J; Cole SW
    Clin Cancer Res; 2016 Jan; 22(1):69-78. PubMed ID: 26286914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Pilot Trial of Patient-Reported Outcomes for Acute Graft-Versus-Host-Disease.
    Patel SS; Hong S; Rybicki L; Farlow S; Dabney J; Kalaycio M; Sobecks R; Majhail NS; Hamilton BK
    Transplant Cell Ther; 2023 Jul; 29(7):465.e1-465.e7. PubMed ID: 37003415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease.
    Kurosawa S; Oshima K; Yamaguchi T; Yanagisawa A; Fukuda T; Kanamori H; Mori T; Takahashi S; Kondo T; Kohno A; Miyamura K; Umemoto Y; Teshima T; Taniguchi S; Yamashita T; Inamoto Y; Kanda Y; Okamoto S; Atsuta Y
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1749-1758. PubMed ID: 28669922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
    Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
    Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.
    Holtick U; Albrecht M; Chemnitz JM; Theurich S; Skoetz N; Scheid C; von Bergwelt-Baildon M
    Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD010189. PubMed ID: 24748537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
    Tomblyn MR; Ewell M; Bredeson C; Kahl BS; Goodman SA; Horowitz MM; Vose JM; Negrin RS; Laport GG
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1051-7. PubMed ID: 21073974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.
    Kharfan-Dabaja M; Mhaskar R; Reljic T; Pidala J; Perkins JB; Djulbegovic B; Kumar A
    Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010280. PubMed ID: 25061777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.
    Phelan R; Im A; Hunter RL; Inamoto Y; Lupo-Stanghellini MT; Rovo A; Badawy SM; Burns L; Eissa H; Murthy HS; Prasad P; Sharma A; Suelzer E; Agrawal V; Aljurf M; Baker K; Basak GW; Buchbinder D; DeFilipp Z; Grkovic LD; Dias A; Einsele H; Eisenberg ML; Epperla N; Farhadfar N; Flatau A; Gale RP; Greinix H; Hamilton BK; Hashmi S; Hematti P; Jamani K; Maharaj D; Murray J; Naik S; Nathan S; Pavletic S; Peric Z; Pulanic D; Ross R; Salonia A; Sanchez-Ortega I; Savani BN; Schechter T; Shah AJ; Smith SM; Snowden JA; Steinberg A; Tremblay D; Vij SC; Walker L; Wolff D; Yared JA; Schoemans H; Tichelli A
    Transplant Cell Ther; 2022 Jun; 28(6):335.e1-335.e17. PubMed ID: 34757220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing the Influence of Different Comorbidities Indexes on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in a Developing Country.
    Teixeira GM; Bittencourt H; de Macedo AV; Martinho GH; Colosimo EA; Rezende SM
    PLoS One; 2015; 10(9):e0137390. PubMed ID: 26394228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.